Page 1

COMPANY ANNOUNCEMENT 19 AUGUST 2026 العسل Lundbeck Financial report for the period 1 January to 30 June 2026 Strong growth from VyeptiⓇ and focused commercial execution drive total revenue growth of + 16 % CER ( + 13 % CER underlying ) in H1 2026 Key highlights Lundbeck's total revenue grew by + 16 % CER¹ ( + 11 % DKK ) to DKK 13,588 million in the first six months of 2026 , with the U.S. and Europe delivering double - digit growth . The performance reflected continued strong commercial momentum , driven by VyeptiⓇ and RexultiⓇ , and was further shaped by the transition to a partnership model in 27 markets² , which is progressing according to plan . Adjusting for the planned one - time DKK 470 million inventory build in these markets , which occurred in the first quarter of 2026 , total underlying revenue grew by + 13 % CER • United States : DKK 7,227 million ( + 20 % CER ; + 11 % DKK ) • Europe : DKK 3,269 million ( + 14 % CER ; + 14 % DKK ; underlying + 4 % CER ) • International Operations : DKK 2,792 million ( + 6 % CER ; + 2 % DKK ; underlying -1 % CER ) Revenue from Lundbeck's strategic brands increased by + 17 % CER ( + 11 % DKK ) , reaching DKK 10,463 million , representing 77 % of total revenue • RexultiⓇ : DKK 3,297 million ( + 17 % CER ; + 8 % DKK ; underlying + 16 % CER ) • VyeptiⓇ : DKK 2,865 million ( + 46 % CER ; + 36 % DKK ; underlying + 46 % CER ) BrintellixⓇ / Trintellix® : DKK 2,331 million ( + 0 % CER ; -2 % DKK ; underlying -5 % CER ) Abilify LAI franchise³ : DKK 1,970 million ( + 7 % CER ; + 4 % DKK ; underlying + 4 % CER ) EBITDA increased to DKK 4,613 million , up + 18 % CER ( + 11 % DKK ) , while adjusted EBITDA reached DKK 4,765 million , up + 19 % CER ( + 13 % DKK ) . EBITDA growth includes the one - time gross profit impact recognized in the first quarter of 2026 from the inventory build , supporting the transition to a partnership model and future market operations . Excluding this , EBITDA increased to DKK 4,199 million , up + 8 % CER ( + 1 % DKK ) , while adjusted EBITDA increased to DKK 4,351 million , up + 10 % CER ( + 3 % DKK ) . The strong performance was mainly driven by VyeptiⓇ and RexultiⓇ , supported by focused commercial execution . This was partially offset by higher cost of sales and higher R & D costs driven by advancing key pipeline assets . In the second quarter of 2026 , adjusted EBITDA grew + 6 % CER , reflecting the normalization of cost phasing as R & D investment accelerated and the Q1 inventory build was a one - time effect . EPS reached DKK 2.83 , increasing by + 36 % DKK , and adjusted EPS reached DKK 3.70 , increasing by + 28 % DKK , reflecting the strong EBIT performance and lower financial expenses . Lundbeck President and CEO , Charl van Zyl said : " We delivered strong commercial performance in the first half of 2026 , with revenue growing 16 % CER , driven primarily by continued momentum for Vyepti® . Our pipeline continues to advance meaningfully , including the completion of enrollment in the DEEP OCEAN trial of bexicaserin . With a strong balance sheet and clear strategic momentum , we are entering the next phase of our strategy with confidence . " Key figures DKK million H1 2026 H1 2025 Change ( CER ) ' Change ( DKK ) Change Change Q2 2026 Q2 2025 ( CER ) ¹ ( DKK ) Revenue 13,588 12,258 16 % 11 % 6,463 6,023 12 % 7 % EBITDA 4,613 4,150 18 % 11 % 1,982 2,006 9 % ( 1 % ) Adjusted EBITDA 4,765 4,221 19 % 13 % 1,982 2,048 6 % ( 3 % ) EPS ( DKK ) 4 2.83 2.08 36 % 1.16 0.95 22 % Adjusted EPS ( DKK ) 3.70 2.88 28 % 1.54 1.35 14 % 1 Change at CER ( Constant Exchange Rates ) excludes the effect of hedging Lundbeck's foreign currency exposure . 2 For further details , see our announcement Lundbeck sharpens commercial focus in line with strategy , initiates partnering in 27 markets by end - 2025 on 9 September 2025 . 3 Abilify long - acting injectable ( LAI ) franchise comprises the following products : Abilify MaintenaⓇ , Abilify MaintenaⓇ 960 mg , and Abilify Asimtufii® . 4 Comparatives were restated to reflect the final purchase - price allocation for the Longboard business combination , for details see note 4.1 Basis of preparation . Company Announcement No. 793/2026 Ottiliavej 9 2500 Valby Copenhagen Phone : +45 3630 1311 www.lundbeck.com Page 1 CVR - no .: 56759913